News
MRI Tool Helps to Predict Conversion to Pediatric MS
- Author:
- Sara Freeman
Major Finding: The presence of one or more T1-weighted hypointense lesions and one or more T2-weighted periventricular lesions significantly...
News
Study Finds Signs of Progression to Clinically Definite MS
- Author:
- Sara Freeman
Major Finding: The independent predictors of clinically definite MS in patients who had not received disease-modifying treatment, included having...
News
MRI Predicts Response After Starting MS Treatment
- Author:
- Sara Freeman
Major Finding: The presence of more than two GdE T1-weighted lesions at 1 year was associated with nearly sixfold greater odds for nonresponse to...
News
Study: Liraglutide Helps Nondiabetics Keep the Weight Off
- Author:
- Sara Freeman
Major Finding: Body weight was decreased by 6.11% in the liraglutide-treated individuals but by just 0.05% in those given placebo (P less than ....
News
MS Trials Show Complexity of Targeting B Cells
- Author:
- Sara Freeman
News
MS Activity Returns Soon After Stopping Natalizumab
- Author:
- Sara Freeman
Major Finding: The estimated percentage of patients who had a clinical relapse or MRI scan meeting rescue criteria was 61% for placebo, 60% for...
News
Weekly Exenatide Similar to Daily Liraglutide
- Author:
- Sara Freeman
News
Daclizumab Shows Promise in Multiple Sclerosis Trial
- Author:
- Sara Freeman
Major Finding: The annualized relapse rate at 1 year was 0.21 for 150 mg daclizumab and 0.23 for 300 mg, compared with 0.46 for placebo (P less...
News
Laquinimod Halted MS Disability But Not Relapses
- Author:
- Sara Freeman
Major Finding: The 2-year annualized relapse rate was not significantly different between laquinimod and placebo (0.28 vs. 0.34, respectively),...
News
Laquinimod Halted MS Disability But Not Relapses
- Author:
- Sara Freeman
Major Finding: The 2-year annualized relapse rate was not significantly different between laquinimod and placebo (0.28 vs. 0.34, respectively),...
News
Alemtuzumab Bests Interferon for Preventing MS Relapse
- Author:
- Sara Freeman
Major Finding: At 2 years, 78% of 376 patients treated with alemtuzumab and 59% of 187 treated with IFNB-1a remained relapse free (P less than ....
News
Possible Cancer Link to Diabetes Drugs Stirs Controversy
- Author:
- Sara Freeman
Major Finding: The risk of pancreatic cancer was increased with exenatide and sitagliptin versus control treatments, with respective odds ratios...
News
Dimethyl Fumarate Halved MS Relapse Rate
- Author:
- Sara Freeman
Major Finding: The cumulative probability of relapse with 240 mg dimethyl fumarate at 2 years was 27% when given twice daily and 26% when given...
News
Conventional LFTs Often Miss Liver Disease in Type 2 Diabetes
- Author:
- Sara Freeman
Major Finding: The positive predictive values of ALT and GGT above normal in predicting fibrosis were low, at 26% and 29%, respectively.
News
Fatty Liver Is Independent Marker of Heart Risk
- Author:
- Sara Freeman